Aprea Therapeutics, Inc. APRE
Aprea Therapeutics, Inc. (Nasdaq: APRE) is an oncology drug developer. Its lead program, APR-1051, is in Phase 1 for biomarker-defined solid tumors (uterine serous carcinoma, cyclin E-overexpressing platinum-resistant ovarian cancer). Its next catalyst on record is APR-1051: Next clinical data update from ACESOT-1051 at a medical meeting (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: APR-1051 — Next clinical data update from ACESOT-1051 at a medical meeting (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| APR-1051 (WEE1 inhibitor) | advanced solid tumors; USC and PROC expansion planned | small molecule | Phase 1 |
| ATRN-119 (ATR inhibitor) | advanced solid tumors | small molecule | Phase 1 |
| APR-246 | — | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.